English
简体中文
Total: £ 56.28
Published Date: 2024-09-13 | Pages: 104 | Tables: 205 | Pharma & Healthcare
The global market for Neuroendocrine Carcinoma Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Neuroendocrine Carcinoma Drugs by region & country, by Type, and by Application.
The Neuroendocrine Carcinoma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma Drugs.
Market Segmentation
By Company
Xiaflex
Novartis AG
Roche
Molecular Insight pharmaceuticals
Callisto Pharmaceuticals
Segment by Type:
Somatostatin Analogs
Targeted Therapy
Chemotherapy
Segment by Application
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neuroendocrine Carcinoma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Neuroendocrine Carcinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Neuroendocrine Carcinoma Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Neuroendocrine Carcinoma Drugs Product Introduction
1.2 Global Neuroendocrine Carcinoma Drugs Market Size Forecast
1.2.1 Global Neuroendocrine Carcinoma Drugs Sales Value (2019-2030)
1.2.2 Global Neuroendocrine Carcinoma Drugs Sales Volume (2019-2030)
1.2.3 Global Neuroendocrine Carcinoma Drugs Sales Price (2019-2030)
1.3 Neuroendocrine Carcinoma Drugs Market Trends & Drivers
1.3.1 Neuroendocrine Carcinoma Drugs Industry Trends
1.3.2 Neuroendocrine Carcinoma Drugs Market Drivers & Opportunity
1.3.3 Neuroendocrine Carcinoma Drugs Market Challenges
1.3.4 Neuroendocrine Carcinoma Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neuroendocrine Carcinoma Drugs Players Revenue Ranking (2023)
2.2 Global Neuroendocrine Carcinoma Drugs Revenue by Company (2019-2024)
2.3 Global Neuroendocrine Carcinoma Drugs Players Sales Volume Ranking (2023)
2.4 Global Neuroendocrine Carcinoma Drugs Sales Volume by Company Players (2019-2024)
2.5 Global Neuroendocrine Carcinoma Drugs Average Price by Company (2019-2024)
2.6 Key Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Neuroendocrine Carcinoma Drugs Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Neuroendocrine Carcinoma Drugs
2.9 Neuroendocrine Carcinoma Drugs Market Competitive Analysis
2.9.1 Neuroendocrine Carcinoma Drugs Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Neuroendocrine Carcinoma Drugs Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Somatostatin Analogs
3.1.2 Targeted Therapy
3.1.3 Chemotherapy
3.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Type
3.2.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neuroendocrine Carcinoma Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Neuroendocrine Carcinoma Drugs Sales Value, by Type (%) (2019-2030)
3.3 Global Neuroendocrine Carcinoma Drugs Sales Volume by Type
3.3.1 Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Neuroendocrine Carcinoma Drugs Sales Volume, by Type (2019-2030)
3.3.3 Global Neuroendocrine Carcinoma Drugs Sales Volume, by Type (%) (2019-2030)
3.4 Global Neuroendocrine Carcinoma Drugs Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinics
4.1.3 Oncology Centres
4.1.4 Ambulatory Surgery Centres
4.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Application
4.2.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neuroendocrine Carcinoma Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Neuroendocrine Carcinoma Drugs Sales Value, by Application (%) (2019-2030)
4.3 Global Neuroendocrine Carcinoma Drugs Sales Volume by Application
4.3.1 Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Neuroendocrine Carcinoma Drugs Sales Volume, by Application (2019-2030)
4.3.3 Global Neuroendocrine Carcinoma Drugs Sales Volume, by Application (%) (2019-2030)
4.4 Global Neuroendocrine Carcinoma Drugs Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Region
5.1.1 Global Neuroendocrine Carcinoma Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2019-2024)
5.1.3 Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2025-2030)
5.1.4 Global Neuroendocrine Carcinoma Drugs Sales Value by Region (%), (2019-2030)
5.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Region
5.2.1 Global Neuroendocrine Carcinoma Drugs Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2019-2024)
5.2.3 Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2025-2030)
5.2.4 Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (%), (2019-2030)
5.3 Global Neuroendocrine Carcinoma Drugs Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
5.4.2 North America Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
5.5.2 Europe Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
5.6.2 Asia Pacific Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
5.7.2 South America Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
5.8.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value
6.2.1 Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.2.2 Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.3.2 United States Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.4.2 Europe Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.5.2 China Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.6.2 Japan Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.7.2 South Korea Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neuroendocrine Carcinoma Drugs Sales Value, 2019-2030
6.9.2 India Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neuroendocrine Carcinoma Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Xiaflex
7.1.1 Xiaflex Company Information
7.1.2 Xiaflex Introduction and Business Overview
7.1.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Xiaflex Neuroendocrine Carcinoma Drugs Product Offerings
7.1.5 Xiaflex Recent Development
7.2 Novartis AG
7.2.1 Novartis AG Company Information
7.2.2 Novartis AG Introduction and Business Overview
7.2.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novartis AG Neuroendocrine Carcinoma Drugs Product Offerings
7.2.5 Novartis AG Recent Development
7.3 Roche
7.3.1 Roche Company Information
7.3.2 Roche Introduction and Business Overview
7.3.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Roche Neuroendocrine Carcinoma Drugs Product Offerings
7.3.5 Roche Recent Development
7.4 Molecular Insight pharmaceuticals
7.4.1 Molecular Insight pharmaceuticals Company Information
7.4.2 Molecular Insight pharmaceuticals Introduction and Business Overview
7.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Offerings
7.4.5 Molecular Insight pharmaceuticals Recent Development
7.5 Callisto Pharmaceuticals
7.5.1 Callisto Pharmaceuticals Company Information
7.5.2 Callisto Pharmaceuticals Introduction and Business Overview
7.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Offerings
7.5.5 Callisto Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Neuroendocrine Carcinoma Drugs Industrial Chain
8.2 Neuroendocrine Carcinoma Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neuroendocrine Carcinoma Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Neuroendocrine Carcinoma Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Neuroendocrine Carcinoma Drugs Market Trends
Table 2. Neuroendocrine Carcinoma Drugs Market Drivers & Opportunity
Table 3. Neuroendocrine Carcinoma Drugs Market Challenges
Table 4. Neuroendocrine Carcinoma Drugs Market Restraints
Table 5. Global Neuroendocrine Carcinoma Drugs Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Company (2019-2024)
Table 7. Global Neuroendocrine Carcinoma Drugs Sales Volume by Company (2019-2024) & (K MT)
Table 8. Global Neuroendocrine Carcinoma Drugs Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Neuroendocrine Carcinoma Drugs Price by Company (2019-2024) & (USD/MT)
Table 10. Key Manufacturers Neuroendocrine Carcinoma Drugs Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Neuroendocrine Carcinoma Drugs Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Neuroendocrine Carcinoma Drugs
Table 13. Global Neuroendocrine Carcinoma Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Neuroendocrine Carcinoma Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K MT)
Table 22. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2019-2024) & (K MT)
Table 23. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2025-2030) & (K MT)
Table 24. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Neuroendocrine Carcinoma Drugs Price by Type (2019-2024) & (USD/MT)
Table 27. Global Neuroendocrine Carcinoma Drugs Price by Type (2025-2030) & (USD/MT)
Table 28. Global Neuroendocrine Carcinoma Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K MT)
Table 34. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2019-2024) & (K MT)
Table 35. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2025-2030) & (K MT)
Table 36. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Neuroendocrine Carcinoma Drugs Price by Application (2019-2024) & (USD/MT)
Table 39. Global Neuroendocrine Carcinoma Drugs Price by Application (2025-2030) & (USD/MT)
Table 40. Global Neuroendocrine Carcinoma Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2019-2024) & (%)
Table 44. Global Neuroendocrine Carcinoma Drugs Sales Value by Region (2025-2030) & (%)
Table 45. Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (K MT): 2019 VS 2023 VS 2030
Table 46. Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2019-2024) & (K MT)
Table 47. Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2025-2030) & (K MT)
Table 48. Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2019-2024) & (%)
Table 49. Global Neuroendocrine Carcinoma Drugs Sales Volume by Region (2025-2030) & (%)
Table 50. Global Neuroendocrine Carcinoma Drugs Average Price by Region (2019-2024) & (USD/MT)
Table 51. Global Neuroendocrine Carcinoma Drugs Average Price by Region (2025-2030) & (USD/MT)
Table 52. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Volume, (2019-2024) & (K MT)
Table 56. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Volume, (2025-2030) & (K MT)
Table 57. Xiaflex Company Information
Table 58. Xiaflex Introduction and Business Overview
Table 59. Xiaflex Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 60. Xiaflex Neuroendocrine Carcinoma Drugs Product Offerings
Table 61. Xiaflex Recent Development
Table 62. Novartis AG Company Information
Table 63. Novartis AG Introduction and Business Overview
Table 64. Novartis AG Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 65. Novartis AG Neuroendocrine Carcinoma Drugs Product Offerings
Table 66. Novartis AG Recent Development
Table 67. Roche Company Information
Table 68. Roche Introduction and Business Overview
Table 69. Roche Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 70. Roche Neuroendocrine Carcinoma Drugs Product Offerings
Table 71. Roche Recent Development
Table 72. Molecular Insight pharmaceuticals Company Information
Table 73. Molecular Insight pharmaceuticals Introduction and Business Overview
Table 74. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 75. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Offerings
Table 76. Molecular Insight pharmaceuticals Recent Development
Table 77. Callisto Pharmaceuticals Company Information
Table 78. Callisto Pharmaceuticals Introduction and Business Overview
Table 79. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 80. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Offerings
Table 81. Callisto Pharmaceuticals Recent Development
Table 82. Key Raw Materials Lists
Table 83. Raw Materials Key Suppliers Lists
Table 84. Neuroendocrine Carcinoma Drugs Downstream Customers
Table 85. Neuroendocrine Carcinoma Drugs Distributors List
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroendocrine Carcinoma Drugs Product Picture
Figure 2. Global Neuroendocrine Carcinoma Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Neuroendocrine Carcinoma Drugs Sales Volume (2019-2030) & (K MT)
Figure 5. Global Neuroendocrine Carcinoma Drugs Sales Price (2019-2030) & (USD/MT)
Figure 6. Neuroendocrine Carcinoma Drugs Report Years Considered
Figure 7. Global Neuroendocrine Carcinoma Drugs Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Neuroendocrine Carcinoma Drugs Players Sales Volume Ranking (2023) & (K MT)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Neuroendocrine Carcinoma Drugs Revenue in 2023
Figure 10. Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Somatostatin Analogs Picture
Figure 12. Targeted Therapy Picture
Figure 13. Chemotherapy Picture
Figure 14. Global Neuroendocrine Carcinoma Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Neuroendocrine Carcinoma Drugs Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Neuroendocrine Carcinoma Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K MT)
Figure 17. Global Neuroendocrine Carcinoma Drugs Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Neuroendocrine Carcinoma Drugs Price by Type (2019-2030) & (USD/MT)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Clinics
Figure 21. Product Picture of Oncology Centres
Figure 22. Product Picture of Ambulatory Surgery Centres
Figure 23. Global Neuroendocrine Carcinoma Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Neuroendocrine Carcinoma Drugs Sales Value Market Share by Application, 2023 & 2030
Figure 25. Global Neuroendocrine Carcinoma Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K MT)
Figure 26. Global Neuroendocrine Carcinoma Drugs Sales Volume Market Share by Application, 2023 & 2030
Figure 27. Global Neuroendocrine Carcinoma Drugs Price by Application (2019-2030) & (USD/MT)
Figure 28. North America Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. North America Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
Figure 30. Europe Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 31. Europe Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
Figure 32. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
Figure 34. South America Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 35. South America Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
Figure 36. Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value (2019-2030) & (US$ Million)
Figure 37. Middle East & Africa Neuroendocrine Carcinoma Drugs Sales Value by Country (%), 2023 VS 2030
Figure 38. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Value (%), (2019-2030)
Figure 39. Key Countries/Regions Neuroendocrine Carcinoma Drugs Sales Volume (%), (2019-2030)
Figure 40. United States Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 41. United States Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 42. United States Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 43. Europe Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 44. Europe Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 45. Europe Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 46. China Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 47. China Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 48. China Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 49. Japan Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 50. Japan Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 51. Japan Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 52. South Korea Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 53. South Korea Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 54. South Korea Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 55. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 56. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 57. Southeast Asia Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 58. India Neuroendocrine Carcinoma Drugs Sales Value, (2019-2030) & (US$ Million)
Figure 59. India Neuroendocrine Carcinoma Drugs Sales Value by Type (%), 2023 VS 2030
Figure 60. India Neuroendocrine Carcinoma Drugs Sales Value by Application (%), 2023 VS 2030
Figure 61. Neuroendocrine Carcinoma Drugs Industrial Chain
Figure 62. Neuroendocrine Carcinoma Drugs Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
